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Abstract
Background: To date, diagnosing food allergies in children still presents a diagnostic dilemma, leading to uncertainty
concerning the definite diagnosis of peanut allergy, as well as to the need for strict diets and the potential need for
adrenalin auto-injectors. This uncertainty in particular is thought to contribute to a lower quality of life. In the
diagnostic process double-blind food challenges are considered the gold standard, but they are time-consuming as well
as potentially hazardous. Other diagnostic tests have been extensively studied and among these component-resolved
diagnostics appeared to present a promising alternative: Ara h2, a peanut storage protein in previous studies showed to
have a significant predictive value.
Methods: Sixty-two out of 72 children, with suspected peanut allergy were analyzed using serum specific IgE and/or
skin prick tests and specific IgE to several components of peanut (Ara h 1, 2, 3, 6, 8, 9). Subsequently, double-blind food
challenges were performed. The correlation between the various diagnostic tests and the overall outcome of the
double-blind food challenges were studied, in particular the severity of the reaction and the eliciting dose.
Results: The double-blind provocation with peanut was positive in 33 children (53 %). There was no relationship
between the eliciting dose and the severity of the reaction. A statistically significant relationship was found between
the skin prick test, specific IgE directed to peanut, Ara h 1, Ara h 2 or Ara h 6, and the outcome of the food challenge
test, in terms of positive or negative (P < .001). However, we did not find any relationship between sensitisation
to peanut extract or the different allergen components and the severity of the reaction or the eliciting dose. There was
no correlation between IgE directed to Ara h 3, Ara h 8, Ara h 9 and the clinical outcome of the food challenge.
Conclusions: This study shows that component-resolved diagnostics is not superior to specific IgE to peanut extract or
to skin prick testing. At present, it cannot replace double-blind placebo-controlled food challenges for determination of
the eliciting dose or the severity of the peanut allergy in our patient group.
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Background
Allergic reactions to peanut vary from mild localized or
gastro-intestinal symptoms to severe generalized reac-
tions affecting the respiratory and/or cardiovascular
system [1]. This allergy can have a significant impact
on the quality of life of children and their parents.
Sometimes the case history is evident and the diagnosis
of anaphylaxis caused by peanut is easily made. How-
ever, reactions to food tend to be difficult to categorize:
the culprit food may remain unclear. Interpreting
symptoms may be difficult, especially when symptoms
are mostly subjective, or remain unrecognized due to
unawareness by caretakers other than parents.
Defining sensitisation to peanut is the next step in
the diagnostic work-up, but is insufficiently conclu-
sive. A subsequent double-blind, placebo-controlled
food challenge (DBPCFC) is considered to be the gold
standard for diagnosing food allergy [2]. However, se-
vere reactions can occur during DBPCFC and are re-
ported in 10–12 % of patients challenged for peanut
in previous studies [3–5]. Furthermore, these chal-
lenges are time-consuming and restricted to a few
well-equipped pediatric hospitals with an allergologi-
cal expert group. Performing a DBPCFC with peanut
will usually confirm or exclude the diagnosis of pea-
nut allergy, thus leading to either specific advice con-
cerning exclusion of peanut from the diet, or to the
possibility of safe introduction.
The main concerns of patients and/or parents of a
child with food allergy are uncertainty and lack of infor-
mation about the eliciting dose and the severity of the
possibly allergic reaction. A recent Dutch study shows
that adult patients, adolescents, and children all benefit
from a negative DBPCFC outcome, but children benefit
even if the outcome of the provocation is positive [6].
Other studies on parents’ perceptions of their child’s
food allergy showed similarly reduced parental concerns
and parental anxiety after food challenge, irrespective of
the outcome of the challenge. It was hypothesized that
these improvements in quality of life were caused by the
fact that a definitive diagnosis of the food allergy pro-
vides a sense of security. This was more important than
fears concerning the challenge procedure. In conclusion,
a definite diagnosis after a positive or negative outcome
improves quality of life [7, 8].
In the past decades component-resolved diagnostics
(CRD) has become increasingly routine, with currently
more than 130 allergenic molecules commercially avail-
able for in vitro specific IgE (sIgE) testing [9–11]. CRD
is an approach used to map the allergen sensitisation of
a patient at a molecular level, using purified natural or
recombinant allergenic molecules instead of allergen ex-
tracts. It is suggested that CRD may be used to assess
the risk of severe systemic reactions in food allergy,
thereby reducing the need for DBPCFC in certain groups
of allergic patients.
In this study we investigated the predictive value of
component-resolved diagnostics for a clinical relevant al-
lergy in a group of consecutive children suspected of a
peanut allergy. Three objectives were of special interest:
a. can we predict the positive or negative outcome of
the DBPCFC with peanut by measuring the levels of
specific IgE to different recombinant peanut allergens?
b. can we predict the eliciting dose (ED) by using CRD?
c. can we predict the severity of the allergic reaction
occurring at the DBPCFC with peanut with this
assay?
d. Especially the second and third questions are of
interest, because these are most important to
parents and determine quality of life and their
ability to cope with the allergy in the future.
Methods
Study design (Additional file 1)
In 2012 and 2013 consecutive patients attending our
outpatient clinic were asked to participate in this pro-
spective cohort study. These children were referred by
general practitioners and pediatricians from surround-
ing hospitals in the western part of the Netherlands.
Allergological examinations were performed in the
Reinier de Graaf Hospital in Delft. All children under-
went serological testing and/or skin testing on the first
visit, provocations were done within approximately 3–4
months after the first visit. Data were collected and
analysed in 2014.
Children were suspected of having a peanut allergy,
because of a history of an allergic reaction in the past
or sensitisation to peanut with no or unknown expos-
ure. In the latter group the sensitisation was found by
previous testing for various reasons. All children under-
went an intensive case history regarding previous pea-
nut ingestion or exposure. Previous reactions to peanut
were reported by the parents of the child and classified
according to the Sampson’s classification based on the
most severe reaction observed, see Table 1 [1]. The
presence of asthma, atopic dermatitis, allergic rhinitis,
and other food allergies was determined in out-patient
clinic consultations before DBPCFC.
Subsequently, sensitisation was measured by skin prick
test, sIgE determination and CRD (Immunocap ISAC).
Within 3 months after the intake a DBPCFC with pea-
nut was performed in the hospital. Only cases with all
measurements available qualified for inclusion.
Data were obtained as part of regular patient care and
used strictly anonymously, according to the code of con-
duct for medical research approved by the hospital’s
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Medical Ethical Committee. Parents gave their written
informed consent before starting the provocation tests.
Tests for sensitisation
Measurement of peanut-specific IgE (sIgE) was per-
formed in all children using the 3gAllergy™ assay on an
IMMULITE® 2000 XPi system (Siemens), according to
the manufacturers instructions. Specific IgE titers were
quantified (KUA/L) with a lower limit of normal of 0.35
KUA/L and an upper detection limit of 100 KUA/L as
proposed by the manufacturer.
Specific IgE directed against peanut protein compo-
nents Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8 and
Ara h 9 was determined using the Immuno Solid-phase
Allergen Chip (ISAC) assay (Thermo Fisher Scientific,
Uppsala, Sweden). Other major allergens from peanut
were not available in this assay. Results were analyzed
on a semiquantitative basis, and IgE values were pre-
sented in arbitrary units called ISAC standardized units
(from 0.3 to 100 ISU). Values of >0.3 ISU were consid-
ered positive. The technique was performed following
the manufacturer’s instructions [12, 13].
Skin prick tests (SPT) were performed within
3 months prior to DBPCFC using a commercial peanut
extract (ALK-Abelló, Nieuwegein, the Netherlands). For
positive and negative control histamine dihydrochlor-
ide, 10 mg/ml and glycerol diluent were used, respect-
ively. Mean diameter of peanut wheal size in
millimeters was calculated from the average of the lar-
gest wheal diameter plus largest wheal diameter per-
pendicular to this. SPT was also evaluated by using the
HEP index (histamine equivalent pricktest), and consid-
ered positive when the wheal was 3 mm greater in
diameter than the negative control and the HEP was
more than 0.3 [14, 15].
DBPCFC for peanut
Challenges were performed in a clinical setting
equipped for resuscitation and monitoring of vital
signs according to protocol. Only clinically stable
children without recent infection, uncontrolled atopic
disease or recent allergic reactions were eligible to
start the challenge procedure. The DBPCFC protocol
for peanut was described earlier by Vlieg & Flinterman
et al. [16, 17]. The challenge was considered positive and
terminated when objective symptoms occurred or when
consistent subjective symptoms occurred on at least two
subsequent doses. The eliciting dose (ED) was determined
as the lowest dose of peanut protein (in mg) eliciting
objective allergic reaction. Symptoms during challenge
were graded after physical examination by one of the
clinical experts and classified based on the most se-
vere reaction observed in an organ system, according to
the Sampson’s classification [1]. Severe food challenge out-
come (FCO) was defined as a positive FCO with a severe
respiratory and/or cardiovascular reaction of Sampson’s
grade 3 or 4. These children were treated with epi-
nephrine intramuscularly. Children with moderate or
mild reactions were defined as having a reaction ac-
cording to Sampson’s grade 2 and 1, respectively.
These reactions were treated with oral antihistamines
only.
The eliciting dose was graded as follows:
– Low dose, reacting on dose 1 (0.84 mg peanut
protein) or dose 2 (1.6 mg peanut protein).
– Medium dose, reacting on dose 3 (8 mg peanut
protein) or dose 4 (42 mg peanut protein).
– High dose, reacting on dose 5 (0.21 gram peanut
protein, 4/10th of a whole peanut) or dose 6
(1.01 gram peanut protein, 2 whole peanuts).
Table 1 Grading of food-induced anaphylaxis according to severity of clinical symptoms [1]















None Change in activity level





of throat pruritus of
tightness
Tachycardia Change in activity
level plus anxiety
4 Any of the above Any of the above
plus diarrhea








feeling of “pending doom”
5 Any of the above Any of the above,
loss of bowel control
Any of the above,
respiratory arrest
Severe bradycardia and/or
hypotension or cardiac arrest
Loss of consciousness
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Statistical methods
Statistical analyses were performed using GraphPad
Prism software package (version 6, GraphPad Software,
Inc., San Diego, CA, USA). Comparisons were consid-
ered significant at a P value less than .05. The
Wilcoxon-Mann-Whitney test was used to compare the
allergic and tolerant groups and the Kruskal-Wallis test
was used to compare the DBPCFC severity score cat-
egories and DBPCFC eliciting dose categories among the
different measurements. The Fisher Exact Probability
test was used to test the correlation between the
DBPCFC severity score and the DBPCFC eliciting dose.
Statistical analyses of logistic regression and correla-
tions were performed using StatGraphics Centurion
XVII software (Version 17.1.08 for MS-Windows;
Statpoint, Inc., Warrenton, VA, USA). To estimate
odds ratios logistic regression with backward factor
selection (P-to-enter .05; P-to-remove.05) was applied,
with DBPCFC outcome as binominal response vari-
able and numerical variables (Ara h components on
ISAC, age) and categorical variables (gender) as fac-
tors. Non-parametric Spearman’s rank correlations
were assessed between numerical factors before estab-
lishing the most adequate logistic regression model.
Where applicable, a P-value < .05 was considered sta-
tistically significant at the 95 % confidence level.
Results
A total of 72 consecutive children were included in this
study. Because of anxiety and therefore lack of vena-
puncture and/or skin testing, 10 patients were excluded
from the final analysis. The cohort predominantly con-
sisted of boys (74 %) and children had a median age of
7.9 years (range 3–16 years). Applying the non-
parametric Kruskal and Wallis test with the Bonferroni
procedure (of pairwise comparisons between the average
ranks of the 2 groups), none of the medians comparisons
between the sexes were statistically significant at the
95 % confidence level for all recombinant peanut aller-
gens tested.
In 37 children (60 %), the history revealed no
known previous ingestion of peanut. Sensitisation to
peanut and/or anxiety for allergic reactions had been
reasons not to introduce peanut in the diet. In 17
children (27.4 %), peanut was ingested with subse-
quent mild to moderate allergic complaints; 8 chil-
dren (13 %) had experienced a severe anaphylactic
reaction to peanut in the past.
Food challenge outcome
The DBPCFC with peanut was positive in 33 children
(53 %). The severity of the reaction was grade 1 in 6
children, grade 2 in 22 children and severe (grade 3,4) in
5 children. The eliciting dose was low in 5 children,
medium in 14 children and high in 14 children. There
was no relationship between the eliciting dose and the
severity of the reaction in the DBPCFC (data not shown).
A statistically significant relationship was shown be-
tween the skin prick test, sIgE directed to peanut, Ara h
1, Ara h 2 or Ara h 6, and the outcome of the food chal-
lenge test, in terms of positive or negative (P < .001,
Fig. 1). Moreover, the sensitivity of sIgE to peanut ex-
tract and the SPT with peanut were 100 %; while using
sIgE to different peanut components several patients
with a clinical relevant peanut allergy were missed.
We did not find a relationship between the sensitisa-
tions to peanut extract or the different allergen compo-
nents and the severity of the reaction (categorised as
severity 1, 2 or 3 & 4) or the eliciting dose (categorised
as 1 & 2, 3 & 4, 5 & 6) (Figs. 1a–e). There was no correl-
ation between IgE directed to Ara h 3, Ara h 8, Ara h 9
and the clinical outcome of the food challenge.
Analysis based on receiver operating characteristics
(ROC curves) showed Ara h 2 and Ara h 6 to be the
best discriminators between peanut allergy and toler-
ance (Fig. 2). Logistic regression analysis confirmed
that Ara h 2 was the best predictor. A statistically
significant model (adjusted percentage of deviance ex-
plained by model = 28 %), without being adequate yet
(Likelihood Ratio test: P < .001) showed an odds ratio
of 2.3 with a 95 % confidence interval ranging from
1.3 to 4.0, leaving only Ara h 2 as an explanatory
variable. Unusual Residuals analyses suggested the
presence of one outlier. After tentative removal of the
outlier the model improved (adjusted percentage of
deviance explained by model = 48 %), became ad-
equate (Likelihood Ratio test: P = .32) and showed an
odds ratio of 11.5 with a 95 % confidence interval
ranging from 2.4 to 54.6, leaving only only Ara h 2
as an explanatory variable. A conclusion from the lo-
gistic regression analyses on this patients cohort is
that we are 95 % confident that a rise in Ara h 2 (in
International Standard Units, used in ISAC) increases
the chance of a positive DBPCFC outcome with at
least 30 % (or 140 % after omitting an outlier). In this
study, Ara h 2 and Ara h 6 were highly correlated
(non-parametric Spearman Rank Correlation: R2 = .81;
i.e., .7 < |r| < .9, only complete data used; results not
shown); moreover, on population level these measur-
ands do not provide independent information since
Ara h 2 and Ara h 6 are being considered very
homologous.
Discussion
Component-resolved diagnostics is becoming increasingly
routine in the Netherlands. It may facilitate the manage-
ment of allergic patients for the physician [9–11]. Know-
ledge of the exact allergenic molecules the patient is
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sensitised to can help predict the likelihood of mild versus
severe systemic food reactions. Some allergens such as the
storage proteins in peanuts and nuts have been shown to
be associated with severe allergic reactions, while other al-
lergens cause mild oral allergy or even positive allergy
tests without clinical relevance. Furthermore, allergens
that are stable to heat and digestion (e.g., Ara h 2 from
peanut and Cor a 9 from hazelnut) are more likely to
cause severe anaphylactic reactions, whereas heat and di-
gestive labile molecules (e.g., Ara h 8 from peanut and
Cor a 1 from hazelnut) are more likely to cause milder,
local allergic reactions or no reactions at all [11, 18].
In a systematic review by Klemans et al. it was stated
that sIgE directed to Ara h 2 was superior in diagnosing
peanut allergy in case of a positive test result, compared
to skin prick test and sIgE to whole peanut extract [19].
They reviewed 21 studies in pediatric cohorts and found
a sensitivity rangeing 66–100 % with a specificity range-
ing 0–95 % (food challenge as gold standard) for skin
prick testing. For sIgE to peanut extract sensitivity
ranged from 80 to 100 % with corresponding specificity
from 0 to 63 %. For sIgE to Ara h 2 sensitivity ranged
from 60 to 100 % with a specificity of 60–96 %. For sIgE
directed to Ara h 1 or Ara h 3 diagnostic values varied
widely; for the components Ara h 5, Ara h 8 and Ara h
9 the sensitivity values were low in all studies. They con-
cluded that sIgE to Ara h 2 had the highest LR+, indicat-
ing that it was the best test to predict peanut allergy.
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Fig. 1 Relationship between sensitisation parameters and outcome of DBPCFC with peanut, in regard to positive/negative, severity score and
eliciting dose. Sensitisation was established by means of sIgE to peanut (a), sIgE to Ara h 1 (b), sIgE to Ara h 2 (c), sIgE to Ara h 6 (d) and skin
prick test with peanut (e). The data are presented as box and whiskers plots (25th to 75th percentiles, median, min en max values), including data
points. The dashed lines represent the cut-off values
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In earlier study cohorts it was found that sIgE to
storage proteins such as Ara h 1, 2, and 3 was associ-
ated with clear peanut allergic reactions; in contrast
to Ara h 8, a PR-10 protein and Bet v 1 homologue,
which is associated with milder or local allergic reac-
tions like oral allergy symptoms [11, 18]. In southern
Europe, the lipid transport protein (LTP) Ara h 9 is a
prevalent sensitising allergen that may act as a
marker of severe anaphylactic reactions to peanut
[20]. It is still not known how prevalent Ara h 9 is in
other geographical regions. Finally, patients with pro-
filine or sensitisation to sugars (carbohydrate cross-
reactive determinants, CCD) in peanut alone, usually
react with no or local oral symptoms and heated pea-
nuts may be tolerated.
In this study we investigated the predictive value of
the presence of specific IgE to recombinant peanut aller-
gens (Ara h 1, 2, 3, 6, 8 and 9) for the outcome of a
DBPCFC with peanut. More specific, the correlation be-
tween sIgE to different peanut components and the
overall outcome of the DBPCFC, the eliciting dose of
the DBPCFC and the severity of the reaction were
studied.
Can we predict the positive or negative outcome of the
DBPCFC with peanut by measuring the levels of specific
IgE to different recombinant peanut allergens?
We found a high negative predictive value for sIgE to
peanut extract (100 %), similar to SPT and superior to
the negative predictive value of specific IgE to individual
peanut components. This means that with a negative test
(sIgE to peanut or SPT), a food challenge will not be ne-
cessary anymore and peanut should be reintroduced into
the diet. Based on the clinical assessment by the special-
ist experienced in allergology this introduction may be
performed either at home (in which case we use a safe
introduction scheme) or in the hospital [21].
The positive predictive value of all the diagnostic tests
(sIgE, SPT, recombinant allergens) was low in our pa-
tient group. This means that in sensitised patients there
is still a considerable chance that the oral provocation
will turn out to be negative.
Can we predict the eliciting dose and/or the severity of
the allergic reaction by using CRD?
Most important, there was no correlation between the
diagnostic tests performed and either the eliciting dose
nor the severity of the allergic reaction during the food
provocation. Hence DBPCFC will therefore be necessary
in the future to determine this important information
for the patients and their parents.
Our results are comparable with a recent study by
Blumchen et al. [22]. They stated that a modified
food challenge procedure in 63 children with peanut
allergy with doses of peanut scheduled 2 h apart,
showed a better reflection of the real-life thresholds
for peanut allergy. They found a mild-to-moderate in-
verse correlation of the markers for sensitisation (sIgE
to peanut, sIgE to Ara h 2 and SPT) with the eliciting
dose at challenge. But, similar to our results, there
was no correlation between the biological markers
tested and the grade of severity of the most severe
objective allergic reaction at challenge.
Bégin et al. investigated whether early CRD at time
of peanut allergy diagnosis in children would provide
information in addition to standard sIgE to better
predict future evolution of the disease [23]. They have
shown, Ara h 1, Ara h 2 and Ara h 3 to be the dom-
inant peanut allergens in this population of very
young children (median age, 14 months). For the
follow-up of a median of 12 years, CRD with major
peanut allergens did not provide additional independent
predictive value for the persistence of peanut allergy.
Study limitations
These data were obtained in a group of children with
either a suspicion of food allergy based on sensitisa-
tion only or a peanut allergic reaction in the past.
This being the major reason for referral to our prac-
tice. To confirm or rule out a clinical reactivity to
peanut we routinely perform a DBPC food challenge.
We were interested to study the applicability of CRD
in this group of children. Other limitations are the
size of the group, the specific region (western part of








Fig. 2 Receiver Operating Curve, data are presented for peanut
components Ara h 1, 2, 3, 6, 8, 9 and peanut extract as area under
the curve (95 % CI)
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recommendation only on peanut allergy. Finally, we
excluded children who recently experienced a clear
clinical reaction to peanut. In this group a DBPC
food challenge will not be necessary to confirm the
diagnosis. Because these patients were not included, it
could have biased this study. In daily practice these
patients are not willing to undergo a provocation and
we intended to test the recombinant allergens on pa-
tient groups with unknown clinical reactivity, as seen
in many pediatric clinics.
Conclusion
This study shows that component-resolved diagnostics is
not superior to sIgE to peanut extract or to skin prick
testing to diagnose peanut allergy. At present, it cannot
replace double-blind placebo-controlled food challenges
for determination of the eliciting dose or the severity of
the peanut allergy in our patient group. Further studies
with larger numbers of patients and other regions are
necessary to investigate the generalizability of these re-
sults in the case of peanut allergy.
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